



18th ICML	International Conference on Malignant Lymphoma Lugano	17–21 June 2025
----------------------	--	--------------------------------

Abstract submission categories (min 1 – max 3)

Basic and Translational Science	<ul style="list-style-type: none"> • Bioinformatics; Computational and Systems Biology • Genomics, Epigenomics, and Other -Omics • Metabolism • Microenvironment • Patient-Derived Xenograft (PDX) Models • Risk Models • Tumor Biology and Heterogeneity • Other
Cancer Health Disparities	
Diagnostic and Prognostic Biomarkers	
Experimental Therapeutics	<ul style="list-style-type: none"> • Cellular therapies • Chemotherapy • Molecular Targeted Therapies • Combination Therapies • Immunotherapy • Radiation Therapy • Targeting the Tumor Microenvironment • Other
Imaging and Early Detection	<ul style="list-style-type: none"> • PET-CT • Liquid biopsy • Minimal residual disease • Other
Late Effects in Lymphoma Survivors	
Lymphoid Cancers	<ul style="list-style-type: none"> • Aggressive B-cell non-Hodgkin lymphoma • Aggressive T-cell non-Hodgkin lymphoma • Canine Lymphoma as a Surrogate • Chronic Lymphocytic Leukemia (CLL) • Cutaneous non-Hodgkin lymphoma • Extranodal non-Hodgkin lymphoma • Hodgkin lymphoma • Hodgkin lymphoma (Pediatric, Adolescent, and Young Adult) • Indolent non-Hodgkin lymphoma • Multiple Myeloma • Non-Hodgkin lymphoma (Pediatric, Adolescent, and Young Adult) • Other

Pathology and Classification of Lymphomas	
Prevention and Cancer Interception	
Therapeutics and Clinical Trials in Lymphoma	<ul style="list-style-type: none"> • Cellular therapies • Chemotherapy • Molecular Targeted Therapies • Combination Therapies • Immunotherapy • Radiation Therapy • Stem Cell Transplant • Targeting the Tumor Microenvironment • Other
Lymphoma Nursing	
Other	